Othenin-Girard P, Borruat X, Bovey E, Pittet N, Herbort C P
Hôpital Jules Gonin, Service d'ophtalmologie, Université de Lausanne.
Klin Monbl Augenheilkd. 1992 May;200(5):362-6. doi: 10.1055/s-2008-1045766.
In a prospective randomized double masked study including 40 patients we evaluated the anti-inflammatory effect of a combination of dexamethasone acetate 0.1% + diclofenac 0.1% drops compared to dexamethasone acetate 0.1% + placebo drops, after ECCE + posterior chamber lens implantation. Anterior chamber (AC) flare and cells were measured with the laser flare-cell meter Kowa FC-1000. The group receiving the dexamethasone-diclofenac combination showed a more rapid decrease of AC flare which was significant at days D3 (P less than 0.003) and D12 (p less than 0.028). The reduction of AC cells was comparable in both groups, showing however a strong tendency toward a lower cell count in the group receiving diclofenac at days D12 and D30 (p less than 0.08). Tolerance of diclofenac was good and comparable to the placebo.
在一项纳入40例患者的前瞻性随机双盲研究中，我们评估了在白内障囊外摘除术（ECCE）联合后房型人工晶状体植入术后，0.1%醋酸地塞米松+0.1%双氯芬酸滴眼液组合与0.1%醋酸地塞米松+安慰剂滴眼液相比的抗炎效果。使用Kowa FC - 1000激光散射细胞仪测量前房（AC）的闪光和细胞数。接受地塞米松 - 双氯芬酸组合治疗的组前房闪光下降更快，在第3天（P<0.003）和第12天（P<0.028）时具有显著差异。两组前房细胞数的减少情况相当，但在第12天和第30天时，接受双氯芬酸治疗的组细胞数有明显更低的趋势（P<0.08）。双氯芬酸的耐受性良好，与安慰剂相当。
